

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	October 12, 2011 November 28, 2011, April 26, 2012, November 16, 2015, April 12, 2024

**Erwinaze<sup>®</sup> (asparaginase erwinia chrysanthemi) and Rylaze<sup>®</sup> (asparaginase erwinia chrysanthemi [recombinant]-rywn)**

**LENGTH OF AUTHORIZATION:** Up to one year

**REVIEW CRITERIA:**

**Erwinaze**

- Patient must be  $\geq 1$  year of age; **AND**
- Patient must have a diagnosis of Acute Lymphoblastic Leukemia verified by progress notes, discharge notes, or diagnosis code(s); **AND**
- Medication must be prescribed by an oncologist; **AND**
- Patient must have a history of serious hypersensitivity reaction (e.g., Grade 3 or higher angioedema, urticaria, rash or erythema, hypotension, bronchospasm, dyspnea, pruritus, etc.) to E. coli-derived asparaginase (e.g., pegaspargase [Oncaspar<sup>®</sup>]). *(Must be clearly documented in official medical records.)*

**Rylaze**

- Patient must be  $\geq 1$  month old; **AND**
- Patient must have a diagnosis of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma verified by progress notes, discharge notes, or diagnosis code(s), **AND**
- Medication must be prescribed by an oncologist; **AND**
- Patient must have a history of serious hypersensitivity reaction (e.g., Grade 3 or higher angioedema, urticaria, rash or erythema, hypotension, bronchospasm, dyspnea, pruritus, etc.) to E. coli-derived asparaginase (e.g., pegaspargase [Oncaspar<sup>®</sup>]). *(Must be clearly documented in official medical records.)*

**CONTINUATION OF THERAPY:**

- Patient met initial review criteria; **AND**
- Documentation of a positive clinical response; **AND**
- Patient has not experienced any treatment-restricting adverse effects; **AND**
- Dosing is appropriate as per labeling or is supported by compendia.

**DOSING & ADMINISTRATION:**

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>